Is Genmab A/S (GMAB) a Buy, Sell, or Hold?
Genmab A/S
NASDAQ:GMAB
$28.73 USD
-$0.07 (-0.24%)
- Volume
- 1.63M
- Average Volume
- 1.94M
- Market Capitalization
- $17.64B
- P/E Ratio
- 21.39
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $35.43
- Year Low
- $21.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.18
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jan van de Winkel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GMAB |
| CUSIP | 372303206 |
| CIK | 0001434265 |
| Web | https://www.genmab.com |
| Phone | 45 70 20 27 28 |
| Currency | USD |
| Employees | 2638 |
| Country | DK |
Liquidity
| Debt-to-Equity Ratio | 0.94 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.18 |
| Quick Ratio | 2.17 |
| Cash Ratio | 1.29 |
Sales & Book Value
| Annual Sales | $3.72B |
| Price / Sales | 1.86 |
| Cash Flow | 14.24 |
| Price / Cash Flow | 19.99 |
| Price / Book | 3.08 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $41.50 |
| Low Stock Price Forecast | $32.00 |
| Forecast Upside/Downside | -28.17% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 17 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.54 |
| Trailing P/E Ratio | 21.39 |
| PEG Ratio | -0.24 |
| P/E Growth | -0.24 |
| Net Income | $963.76M |
| Net Margin | 8.72% |
| Pretax Margin | 10.99% |
| Return on Equity | 14.55% |
| Return on Assets | 6.64% |
Financials Score
| AltmanZ Score | 11.57 |
| Piotroski Score | 6.00 |
| Working Capital | 1.39B |
| Total Assets | 12.38B |
| Ebit | 1.2B |
| Market Cap | 115.36B |
| Total Liabilities | 6.69B |
Poll Results
About Genmab A/S (NASDAQ:GMAB) Stock
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a ro ... bust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
2026-07-07 12:15:36
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
2026-07-06 13:59:01
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE FL-1 trial, fixed-duration TEPKINLYR2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete response Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLYR2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).
2026-07-06 13:45:00
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial that evaluated fixed-duration TEPKINLY + R2 compared to standard of care R2. “Follicular.
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
2026-06-30 12:31:46
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
2026-06-30 05:35:00
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
2026-06-29 16:14:00
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL COPENHAGEN, Denmark; June 29, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatment. Based on topline results, the trial met its primary objective, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS).
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2026-06-16 15:12:00
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Major Shareholder Announcement
2026-06-15 12:04:00
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
Frequently Asked Questions
-
What is the current Genmab A/S (GMAB) stock price?
-
Genmab A/S(NASDAQ:GMAB) stock price is $28.73 in the last trading session. During the trading session, GMAB stock reached the peak price of $35.43 while $20.995 was the lowest point it dropped to. The percentage change in GMAB stock occurred in the recent session was --0.24% while the dollar amount for the price change in GMAB stock was -$-0.07.
-
GMAB's industry and sector of operation?
-
The NASDAQ listed GMAB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GMAB?
-
Judith V. Klimovsky | Executive Vice President & Chief Development Officer
Martine J. van Vugt | Executive Vice President & Chief Strategy Officer
Christopher Cozic | Executive Vice President & Chief People Officer
Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer
Rayne Waller | Executive Vice President & Chief Technical Operations Officer -
How many employees does GMAB have?
-
Number of GMAB employees currently stands at 2638. GMAB operates from Kalvebod Brygge 43, Copenhagen, CD 1560, DK.
-
Link for GMAB official website?
-
Official Website of GMAB is: https://www.genmab.com
-
How do I contact GMAB?
-
GMAB could be contacted at phone #45 70 20 27 28 and can also be accessed through its website. GMAB operates from Kalvebod Brygge 43, Copenhagen, CD 1560, DK.
-
How many shares of GMAB are traded daily?
-
The average number of GMAB shares traded daily for last 3 months was 1.94M.
-
What is the market cap of GMAB currently?
-
The market value of GMAB currently stands at $17.64B with its latest stock price at $28.73